Idorsia Advances Lupus Drug Into Phase III Despite Mid-Stage Fail
Phase IIb Study Of Cenerimod Not Statistically Significant
Executive Summary
The Swiss biotech is confident its S1P1 receptor modulator can be an effective treatment for lupus but the move into late-stage studies has raised some eyebrows.